A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics

Autor:	Peter M. Hoogerbrugge, Hanka Venselaar, Debbie M. Roeleveld, C Lanvers, Laurens T. van der Meer, Frank N. van Leeuwen, Marloes Levers, Joachim Boos, Esmé Waanders, Roger J. M. Brüggemann, Roland P. Kuiper, D. Maroeska te Loo
Rok vydání:	2014
Předmět:	Asparaginase medicine.diagnostic_test business.industry Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2] Lymphoblastic Leukemia Immunology Cell Biology Hematology Rare cancers Radboud Institute for Molecular Life Sciences [Radboudumc 9] Pharmacology Biochemistry Cathepsin B chemistry.chemical_compound lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] Germline mutation Pharmacokinetics chemistry Therapeutic drug monitoring hemic and lymphatic diseases Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14] medicine business Nanomedicine Radboud Institute for Molecular Life Sciences [Radboudumc 19] Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Zdroj:	Blood, 124, 3027-9 Blood, 124, 19, pp. 3027-9 Blood, 124(19), 3027-3029. American Society of Hematology
ISSN:	1528-0020 0006-4971
Popis:	To the editor: l-Asparaginase (ASNase) is a key component of protocols used to treat acute lymphoblastic leukemia (ALL). Poorly understood interpatient differences in ASNase pharmacokinetics demand therapeutic drug monitoring to prevent patients from receiving an inadequate dose.[1][1] Although it
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca92abd7213f41cc98a0b9d43ca7d581 https://doi.org/10.1182/blood-2014-06-582627 Zobrazit plný text záznamu